Three Firms Guide Catalent's $140M Pharma Biz Buy
Drug development and delivery company Catalent Inc. said on Tuesday that it has agreed to acquire Juniper Pharmaceuticals Inc. in a deal that carries an equity value of approximately $139.6 million...To view the full article, register now.
Already a subscriber? Click here to view full article